<p>德国曼海姆，2025 年 4 月 21 日（GLOBE NEWSWIRE）——Affimed N.V.是一家临床阶段的免疫肿瘤学公司，致力于让患者恢复与生俱来的抗癌能力，今天宣布已收到纳斯达克证券市场有限责任公司（“纳斯达克”）上市资格部门于 2025 年 4 月 15 日发出的书面通知（“通知”），该通知指出，在过去的 30 个连续交易日中，公司普通股的出价价格已低于纳斯达克持续上市所需的最低每股 1.00 美元的要求，依据纳斯达克上市规则 5450(a)(1)（“最低出价规则”）。</p>
<p>根据纳斯达克上市规则 5810(c)(3)(A)，公司获得了 180 个日历天的初始期限，直到 2025 年 10 月 13 日，以恢复合规。如果公司在此期间未能恢复对最低出价规则的合规性，公司可能考虑申请将其证券从纳斯达克全球精选市场转移到纳斯达克资本市场，前提是公司满足持续上市所需的公众持股市值和纳斯达克资本市场初始上市的所有其他适用要求（不包括出价价格要求）。此类转移将为公司提供额外的 180 个日历天，直到 2025 年 4 月 13 日，以恢复合规。不能保证公司在适用的情况下有资格获得额外的 180 个日历天的合规期，或纳斯达克工作人员会批准公司的持续上市请求。</p>
<p>该通知对公司普通股的上市或交易没有立即影响。</p>
<p>公司打算监测其普通股的出价价格，并考虑可用选项以恢复对最低出价规则的合规性。</p>
<p><strong>关于 Affimed N.V.</strong></p>
<p>Affimed 是一家临床阶段的免疫肿瘤学公司，致力于通过实现先天免疫系统未开发的潜力，让患者恢复与生俱来的抗癌能力。公司的先天细胞结合剂（ICE®）使肿瘤靶向方法能够识别并杀死多种血液和实体肿瘤。ICE®是在公司的专有 ROCK®平台上生成的，该平台可预测性地生成定制分子，利用先天免疫细胞的力量摧毁肿瘤细胞。多种 ICE®分子正在临床开发中，作为单药或联合疗法进行研究。Affimed 总部位于德国曼海姆，由一支经验丰富的生物技术和制药领导团队领导，他们团结在一个大胆的愿景下，旨在阻止癌症干扰患者的生活。有关公司人员、产品管道和合作伙伴的更多信息，请访问：www.affimed.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。除历史事实陈述外的所有声明均为前瞻性声明，通常用 “预期”、“相信”、“可能”、“估计”、“期望”、“目标”、“打算”、“期待”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“将”、“会” 和类似表达来表示。前瞻性声明包括但不限于关于公司对最低出价规则的合规性以及公司普通股的上市或交易的声明。由于某些风险、不确定性和其他因素，实际结果可能与公司前瞻性声明所预期的结果有重大差异，这些因素在公司向证券交易委员会提交的文件中 “风险因素” 标题下进行了描述。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过度依赖，公司也不承担更新这些前瞻性声明的义务，即使未来有新信息可用。</p>
<p><strong>投资者关系联系人</strong></p>
<p>亚历山大·富杜基迪斯</p>
<p>投资者关系总监</p>
<p>电子邮件：a.fudukidis@affimed.com</p>
<p>电话：+1 (917) 436-8102</p>
<p><strong>媒体联系人</strong></p>
<p>玛丽·贝丝·桑丁</p>
<p>市场与传播副总裁</p>
<p>电子邮件：m.sandin@affimed.com</p>

AFMD

AFMDQ

<p>Affimed N.V. 收到了纳斯达克的通知，指出其普通股在连续 30 个交易日内收盘价低于最低竞标价 1.00 美元。该公司有直到 2025 年 10 月 13 日的时间来恢复合规。如果未能成功，它可以申请转移到纳斯达克资本市场，获得额外的 180 天。该通知不会影响当前的上市或股票交易。Affimed 专注于免疫肿瘤学和开发抗癌疗法</p>

<p>MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) — Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).</p>
<div class="lb-trans"><p>德国曼海姆，2025 年 4 月 21 日（GLOBE NEWSWIRE）——Affimed N.V.是一家临床阶段的免疫肿瘤学公司，致力于让患者恢复与生俱来的抗癌能力，今天宣布已收到纳斯达克证券市场有限责任公司（“纳斯达克”）上市资格部门于 2025 年 4 月 15 日发出的书面通知（“通知”），该通知指出，在过去的 30 个连续交易日中，公司普通股的出价价格已低于纳斯达克持续上市所需的最低每股 1.00 美元的要求，依据纳斯达克上市规则 5450(a)(1)（“最低出价规则”）。</p>
</div><p>In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5810(c)(3)(A)，公司获得了 180 个日历天的初始期限，直到 2025 年 10 月 13 日，以恢复合规。如果公司在此期间未能恢复对最低出价规则的合规性，公司可能考虑申请将其证券从纳斯达克全球精选市场转移到纳斯达克资本市场，前提是公司满足持续上市所需的公众持股市值和纳斯达克资本市场初始上市的所有其他适用要求（不包括出价价格要求）。此类转移将为公司提供额外的 180 个日历天，直到 2025 年 4 月 13 日，以恢复合规。不能保证公司在适用的情况下有资格获得额外的 180 个日历天的合规期，或纳斯达克工作人员会批准公司的持续上市请求。</p>
</div><p>The Notice has no immediate effect on the listing or trading of the Company’s common shares.</p>
<div class="lb-trans"><p>该通知对公司普通股的上市或交易没有立即影响。</p>
</div><p>The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.</p>
<div class="lb-trans"><p>公司打算监测其普通股的出价价格，并考虑可用选项以恢复对最低出价规则的合规性。</p>
</div><p><strong>About Affimed N.V.</strong></p>
<div class="lb-trans"><p><strong>关于 Affimed N.V.</strong></p>
</div><p>Affimed  is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.</p>
<div class="lb-trans"><p>Affimed 是一家临床阶段的免疫肿瘤学公司，致力于通过实现先天免疫系统未开发的潜力，让患者恢复与生俱来的抗癌能力。公司的先天细胞结合剂（ICE®）使肿瘤靶向方法能够识别并杀死多种血液和实体肿瘤。ICE®是在公司的专有 ROCK®平台上生成的，该平台可预测性地生成定制分子，利用先天免疫细胞的力量摧毁肿瘤细胞。多种 ICE®分子正在临床开发中，作为单药或联合疗法进行研究。Affimed 总部位于德国曼海姆，由一支经验丰富的生物技术和制药领导团队领导，他们团结在一个大胆的愿景下，旨在阻止癌症干扰患者的生活。有关公司人员、产品管道和合作伙伴的更多信息，请访问：www.affimed.com。</p>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements include, among other things, statements regarding the Company’s compliance with the Minimum Bid Price Rule and listing or trading of the Company’s common shares. Actual results may differ materially from the results anticipated by the Company’s forward-looking statements due to certain risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。除历史事实陈述外的所有声明均为前瞻性声明，通常用 “预期”、“相信”、“可能”、“估计”、“期望”、“目标”、“打算”、“期待”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“将”、“会” 和类似表达来表示。前瞻性声明包括但不限于关于公司对最低出价规则的合规性以及公司普通股的上市或交易的声明。由于某些风险、不确定性和其他因素，实际结果可能与公司前瞻性声明所预期的结果有重大差异，这些因素在公司向证券交易委员会提交的文件中 “风险因素” 标题下进行了描述。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过度依赖，公司也不承担更新这些前瞻性声明的义务，即使未来有新信息可用。</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>Alexander Fudukidis</p>
<div class="lb-trans"><p>亚历山大·富杜基迪斯</p>
</div><p>Director, Investor Relations</p>
<div class="lb-trans"><p>投资者关系总监</p>
</div><p>E-Mail: a.fudukidis@affimed.com</p>
<div class="lb-trans"><p>电子邮件：a.fudukidis@affimed.com</p>
</div><p>Tel.: +1 (917) 436-8102</p>
<div class="lb-trans"><p>电话：+1 (917) 436-8102</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系人</strong></p>
</div><p>Mary Beth Sandin</p>
<div class="lb-trans"><p>玛丽·贝丝·桑丁</p>
</div><p>Vice President, Marketing and Communications</p>
<div class="lb-trans"><p>市场与传播副总裁</p>
</div><p>E-Mail: m.sandin@affimed.com</p>
<div class="lb-trans"><p>电子邮件：m.sandin@affimed.com</p>
</div>

Affimed 宣布收到 NASDAQ 关于最低出价要求的缺陷通知